Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNSHINE: Secukinumab in Moderate to Severe Hidradenitis Suppurativa
jRCT2080224602Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (3 arms), sponsored by Novartis. Primary endpoint: HiSCR50 response at week 16. Started Mar 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2080224602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224602.